Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma

Yutaka Midorikawa1*, Tadatoshi Takayama1*, Hisashi Nakayama1, Tokio Higaki1, Masamichi Moriguchi1, Kyoji Moriya2, Tatsuo Kanda3, Shunichi Matsuoka3 and Mitsuhiko Moriyama3

Abstract

Background: Prior hepatitis B virus infection (PBI) may increase the risk of developing hepatocellular carcinoma (HCC), but the impact of PBI on clinical outcomes following treatment for HCC remains unknown. The aim of this study was to clarify whether PBI affects clinical outcomes after liver resection for hepatitis C virus (HCV)-related HCC by retrospective cohort study.

Methods: PBI patients were defined as those negative for hepatitis B surface antigen and positive for anti-hepatitis B core antibody. Surgical outcomes of HCV-related HCC patients with PBI were compared to those without PBI. Survival of patients with non-B non-C HCC with and without PBI were also compared.

Results: In the HCV group, the median overall survival of 165 patients with PBI was 4.7 years (95% confidence interval [CI], 3.9–5.9), and was significantly shorter compared with 263 patients without PBI (6.6 years [5.3–9.8]; p = 0.015). Conversely, there was no significant difference in recurrence-free survival between the two groups (1.8 years [95% CI, 1.4–2.0] vs 2.0 years [1.7–2.3]; p = 0.205). On Cox proportional hazards regression model, independent factors for overall survival were PBI (hazard ratio 1.38 [95% CI, 1.02–1.87]; p = 0.033), multiple tumors (p = 0.007), tumor size (p = 0.002), and liver cirrhosis (p < 0.001). On the other hand, in the non-B non-C HCC group, both the median overall survival (6.5 years [95% CI, 4.8–7.1]) and recurrence-free survival (2.4 years, [95% CI, 1.5–3.3]) in 104 patients with PBI were not significantly different from those (7.5 years [5.5–NA; p = 0.932]; and 2.2 years [1.7–2.7; p = 0.983]) in 213 patients without PBI.

Conclusions: PBI and HCV in conjunction with each other affect the survival of patients that have undergone resection for HCC.

Keywords: Prior hepatitis B virus infection, Chronic hepatitis C virus infection, Liver resection, Hepatocellular carcinoma

Background

Prior hepatitis B virus (HBV) infection (PBI) is evidenced by isolated IgG anti hepatitis B core antibody (HBcAb) positivity, while occult HBV infection (OBI) is defined as the presence of HBV DNA in the liver of patients without hepatitis B surface antigen (HBsAg) [1]. Despite the disappearance of serum HBsAg after spontaneous regression or hepatitis B treatment with nucleoside analogues, for example, some patients are at risk of developing hepatocellular carcinoma (HCC) [2, 3].

PBI or OBI may play a pivotal role in the progression of liver fibrosis in patients with chronic hepatitis C virus (HCV) infection [4–7], and may also be a risk factor for HCC by indirectly causing persistent hepatic inflammation and fibrosis, as well as through its direct proto-oncogenic effect [4, 8, 9]. Consequently, OBI as a co-factor could impact the life-expectancy of chronic HCV patients with OBI compared with those without OBI [9]. However, there are several conflicting reports that indicate there is no association between PBI or OBI and the progression to
cirrhosis in chronic HCV patients [10, 11]. Likewise, neither prior exposure to HBV nor OBI are significant factors in HCC development in chronic HCV patients [12–14]. However, there have been a few reports from a small cohort on an association between previous infection of HBV and clinical outcome following treatment for HCC [15, 16]. Thus, the impact of PBI or OBI on clinical outcomes of chronic HCV patients remains controversial and unresolved [17].

Reactivation of HBV, both in prior and overt infection, is characterized by a marked enhancement of viral replication under immunosuppressive conditions [18–20]. Therefore, PBI itself does not seem to exacerbate chronic liver disease preceding hepatocarcinogenesis, but may negatively influence the outcomes of chronic liver disease through the co-existence of other related diseases such as HCV or human immunodeficiency virus infection [21].

The aim of the current study was to demonstrate whether PBI and HCV could co-affect the clinical outcomes of patients undergoing liver resection for HCC.

Methods

Patients

From 2004 to 2016, HBsAg-negative patients who underwent curative liver resection for HCC in Nihon University Itabashi Hospital were included in this study. Each participant provided written, informed consent, and this study was approved by the institutional review board of Nihon University. All patients were closely observed during each outpatient visit post-surgery. PBI patients were defined as those who were negative for HBsAg, but positive for HBcAb [22, 23]. HCV patients were defined as those positive for HCV antibody and HCV-RNA detected. Clinical characteristics and outcomes were compared between patients with and without PBI.

Inclusion and exclusion criteria

Patients who underwent initial liver resection for HCC, but were positive for HBsAg were excluded from the study. Patients who were negative for HBsAg and HBcAb but positive for HbsAb, and those who were positive for HCV antibody but negative for HCV-RNA were also excluded. In addition, patients whose HBsAb or HbcAb status had not been determined were also excluded.

Indications for liver resection

Indicators for liver resection were determined by assessing the liver functional reserve according to Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan [24]. Briefly, liver resection was contraindicated in patients who had refractory ascites, hepatic encephalopathy, or both [25]. Patients with up to three lesions were candidates for liver resection.

In order to assess the existence of esophageal varices, gastrointestinal endoscopy was performed preoperatively for all candidates considered eligible for liver resection. Patients with F3 varices (largest size) or F2 varices (enlarged tortuous) or blue varices positive for red color signs were treated prophylactically using esophageal variceal ligation [26].

Surgical procedures

Liver resection was performed on all patients according to criteria based on liver function, as described previously [27]. Briefly, transection of the liver was performed under ultrasonographic guidance using the clamp-crushing method with the inflow-blood-occlusion technique. Curative resection was defined as the complete removal of recognizable HCC diagnosed preoperatively. Postoperative complications were stratified according to the Clavien-Dindo classification [28], which defines morbidities as complications with a score of ≥ IIIa. Complications specific to liver resection were defined as previously described [29].

Follow-up after surgery

All patients were followed for postoperative recurrence, as described previously [30]. Briefly, tumor marker levels were measured, and imaging studies, including computed tomography and ultrasonography, were performed every 3 months on all patients. Recurrence was diagnosed by dynamic computed tomography and/or gadolinium-ethoxybenzyl-diethyleneetriamine pentaacetic acid-enhanced magnetic resonance imaging. The date of recurrence was defined as the date of examination when the recurrence of HCC was detected. In patients with recurrent HCC, the recurrence-free period was defined as the time from the date of surgery to the date of recurrence. Recurrent HCC was managed aggressively by repeated liver resection, transcatheter arterial chemoembolization, radiofrequency ablation, and chemotherapy according to the HCC status and liver function at the time of recurrence. Liver function was estimated 6 months after operation based on Child-Pugh classification.

Statistical analysis

Data collected from each group were statistically analyzed with Fisher’s exact test and the Wilcoxon rank-sum test. Survival curves were generated using the Kaplan–Meier method and compared by the log-rank test. Prognostic factors for overall survival were identified with the Cox proportional hazards regression model. A p value of less than 0.10 was set as the cut-off value for elimination. The following 25 variables considered as potential confounders were examined: age (≥ 75 years vs < 75 years),
sex, PBI, alcohol abuse, diabetes mellitus, esophageal varices, AST (≥ 80 U/L vs < 80 U/L), ALT (≥ 80 U/L vs < 80 U/L), platelet count (≥ 10 × 10^4 μL vs < 10 × 10^4 μL), creatinine (≥ 1.2 mg/dL vs < 1.2 mg/dL), Child-Pugh classification (A vs B), indocyanine green clearance rate at 15 min (≥ 15% vs < 15%), serum alpha-fetoprotein level (≥ 100 ng/mL vs < 100 ng/mL), serum des-gamma-carboxy prothrombin level (≥ 100 ng/mL vs < 100 ng/mL), operation time (≥ 300 min vs < 300 min), clamp time (≥ 75 min vs < 75 min), bleeding (≥ 300 mL vs < 300 mL), transfusion, resection (anatomic vs non-anatomic), multiple tumors, tumor size (≥ 3.0 cm vs < 3.0 cm), differentiation grade (well-differentiated vs moderately differentiated vs poorly differentiated), tumor thrombus of the portal vein and hepatic vein, tumor exposure at surgery, and liver cirrhosis. In all analyses, a p value < 0.05 was considered to be statistically significant.

Results

Patients

Of the 1053 total patients that underwent curative liver resection for HCC during the time period of the study, 872 (82.8%) were negative for HBsAg (Fig. 1). After excluding patients based on the criteria described above, 428 (40.6%) patients, including 165 (18.6%) patients with PBI, were positive for HCV antibody and HCV-RNA; and 317 (30.1%) patients, including 104 (9.8%) patients with PBI were negative for HCV antibody. The demographics and background information for the HCV-positive patients are listed in Table 1. The frequency of alcohol abuse also trended higher in the PBI patients compared to the non-PBI patients (23.6% vs. 16.7%, respectively), but statistical significance was not detected (p = 0.080). As seen in Table 2, there was no significant or trending variable between the PBI and non-PBI patients in the group of HCC patients negative for HCV antibody (non-B non-C).

Operative data

Among the patients positive for HCV antibody and HCV-RNA, the amount of bleeding during surgery for PBI patients (median 316 mL; range, 5–3887) was significantly greater compared to that of non-PBI patients (240 mL; 10–4530; p = 0.029) (Table 1). In comparison, there was no significant variable between the PBI and non-PBI patients negative for HCV (Table 2). Complication rates and histological diagnosis were also not significantly different between the two PBI groups in both HCV-positive and HCV-negative patients.

Survival of HCV-positive patients

After a median follow-up of 3.6 years (range, 0.2–14.2), a total of 290 patients (67.7%) experienced HCC recurrence; 277 patients (95.5%) in the remnant liver, eight patients (2.7%) in distant sites such as the lung, bone, and lymph nodes, and five patients (1.7%) with both intra- and extra-hepatic recurrences. The treatments for recurrent HCC were not significantly different between the two groups (Table 3). During the follow-up period, 105 (63.6%) patients with PBI and 190 (72.2%) patients

Fig. 1 Flow diagram detailing patient recruitment and follow-up study group assignment. The number within each group is indicated (n). HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HBsAb, anti-hepatitis B surface antibody; HbcAb, anti-hepatitis B core antibody; HCV, hepatitis C virus; PBI, prior hepatitis B virus infection.
without PBI were diagnosed as Child-Pugh classification A ($p = 0.068$).

In the patients with HCV-positive, the median overall survival of PBI patients was 4.7 years (95% confidence interval [CI], 3.9–5.9), which was significantly shorter compared with that of non-PBI patients (6.6 years, 5.3–9.8; $p = 0.015$) (Fig. 2). On the other hand, there was no significant difference in the median recurrence-free survival between the two groups (1.8 years, [95% CI, 1.4–2.0] vs 2.0 years, 1.7–2.3; $p = 0.205$). The overall survival and recurrence-free survival rates at 5 years were 45.9 and 17.0% in PBI patients, respectively, and 62.0 and 22.1% in non-PBI.

### Table 1 Patient background (HCV-positive)

|                         | PBI ($n = 165$) | Non-PBI ($n = 263$) | $P$ |
|-------------------------|-----------------|---------------------|-----|
| Age, years              | 71 (53–85)      | 70 (32–86)          | 0.139 |
| Sex, male (%)           | 121 (73.3)      | 183 (69.5)          | 0.444 |
| Alcohol (%)             | 39 (23.6)       | 44 (16.7)           | 0.080 |
| Diabetes mellitus (%)   | 40 (24.2)       | 74 (28.1)           | 0.560 |
| Varices (%)             | 48 (29.0)       | 75 (28.5)           | 0.912 |
| Platelet count          | 13.3 (3.2–35.1) | 11.7 (3.2–66.0)     | 0.133 |
| Creatinine              | 0.75 (0.35–8.34)| 9.24 (0.34–9.24)    | 0.359 |
| Child-Pugh, A (%)       | 124 (75.1)      | 204 (77.5)          | 0.560 |
| ICGR15, %               | 15.2 (3.6–48.4)| 14.8 (2.0–65.5)     | 0.974 |
| Alpha-fetoprotein, ng/mL| 25 (1–23,881)   | 18 (1–93,075)       | 0.259 |
| DCP                     | 45 (2–64,386)   | 44 (1–75,000)       | 0.591 |

### Table 2 Patient background (non-B non-C)

|                         | PBI ($n = 104$) | Non-PBI ($n = 213$) | $P$ |
|-------------------------|-----------------|---------------------|-----|
| Age, years              | 70 (44–85)      | 69 (36–84)          | 0.250 |
| Sex, male (%)           | 86 (82.6)       | 177 (83.0)          | 1.000 |
| Alcohol (%)             | 45 (43.2)       | 82 (38.4)           | 0.464 |
| Diabetes mellitus (%)   | 50 (48.0)       | 96 (45.0)           | 0.632 |
| Varices (%)             | 18 (17.3)       | 33 (15.4)           | 0.745 |
| Platelet count          | 180 (43–66.5)   | 177 (3.7–44.3)      | 0.851 |
| Creatinine              | 0.78 (0.35–2.44)| 0.78 (0.36–2.37)    | 0.448 |
| Child-Pugh, A (%)       | 102 (90.3)      | 190 (89.2)          | 0.846 |
| ICGR15, %               | 10.6 (2.3–48.0)| 11.8 (1.3–74.6)     | 0.254 |
| Alpha-fetoprotein, ng/mL| 7 (1–145,900)   | 7 (1–39,596)        | 0.578 |
| DCP                     | 126 (6–75,000)  | 142 (8–75,000)      | 0.553 |

### Table 3 Treatment after recurrence (HCV positive)

| Treatments             | PBI ($n = 117$) | Control ($n = 173$) | $P$ |
|------------------------|-----------------|---------------------|-----|
| Resection*             | 48 (41.0)       | 65 (37.5)           | 0.623 |
| Transcatheter arterial chemoembolization | 58 (49.5)       | 96 (55.4)           | 0.339 |
| Radiofrequency ablation | 3 (2.5)         | 4 (2.3)             | 1.000 |
| Chemotherapy           | 4 (3.4)         | 4 (3.7)             | 0.718 |
| Radiation              | 1 (0.8)         | 2 (1.1)             | 1.000 |
| None                   | 3 (2.5)         | 2 (1.1)             | 0.396 |

$HCV$ Hepatitis C virus, $PBI$ Prior hepatitis B virus infection, $ICGR15$ Indocyanine green clearance rate at 15 min, $DCP$ Des-gamma carboxyprothrombin

$*$including resection for extra-hepatic tumors
patients, respectively. On multivariate analysis, independent factors for overall survival were PBI (hazard ratio 1.38 [95% CI, 1.02–1.87]; p = 0.033), multiple tumors (p = 0.007), tumor size (p = 0.002), and liver cirrhosis (p < 0.001) (Table 4).

Survival of non-B non-C patients
After a median follow-up of 3.0 years (range, 0.2–12.8 years) for the non-B non-C patients in the study, a total of 192 patients (60.5%) experienced HCC recurrence; 160 patients (83.3%) in the remnant liver, 22 patients (11.4%) in distant sites, and 10 patients (5.2%) with both intra- and extra-hepatic recurrences.

For the 104 patients with PBI and the 213 patients without PBI in this group, the median overall survival was 6.5 years (95% CI, 4.8–7.1) and 7.5 years (5.5–NA; p = 0.932), respectively. The recurrence-free survivals were 2.4 years (95% CI, 1.5–3.3) and 2.2 years (1.7–2.7; p = 0.983), respectively (Fig. 3). The 5-year overall survival rates were 61.2 and 59.9%, and 5-year recurrence-free survival rates were 25.3 and 27.7% in the two groups, respectively.

Discussion
We found that PBI was an unfavorable prognostic factor, negatively impacting survival rates following liver resection for HCV-related HCC, while it did not affect the surgical outcomes in non-B non-C HCC patients. Therefore, our findings suggest that PBI and HCV in conjunction with each other affect the survival of patients that have undergone resection for HCC.

Consistent with the previous report that HCV and OBI co-infected patients are at an increased risk of lower survival [9], we showed that overall survival following resection for HCC was significantly shorter in HCV

Table 4 Prognostic factors for survival in patients with HCV

| Variables                  | Univariate |     |     | Multivariate |     |     |
|----------------------------|------------|-----|-----|--------------|-----|-----|
| Age                        | 1.16       | 0.78–1.68 | 0.446 |              |     |     |
| Gender, male               | 0.79       | 0.54–1.14 | 0.215 |              |     |     |
| Prior HBV infection        | 1.45       | 1.06–1.99 | 0.019 | 1.38         | 1.02–1.87 | 0.033 |
| Alcoholic                  | 0.82       | 0.54–1.22 | 0.348 |              |     |     |
| Diabetes mellitus          | 1.05       | 0.72–1.51 | 0.755 |              |     |     |
| Varices                    | 1.05       | 0.74–1.49 | 0.747 |              |     |     |
| AST                        | 0.93       | 0.61–1.37 | 0.747 |              |     |     |
| ALT                        | 0.69       | 0.45–1.03 | 0.171 |              |     |     |
| Platelet count             | 0.84       | 0.62–1.16 | 0.303 |              |     |     |
| Creatinine                 | 1.46       | 0.72–2.62 | 0.242 |              |     |     |
| Child-Pugh, B              | 1.17       | 0.79–1.72 | 0.413 |              |     |     |
| ICGR15                      | 1.05       | 0.74–1.48 | 0.762 |              |     |     |
| Alpha-fetoprotein          | 0.91       | 0.62–1.29 | 0.617 |              |     |     |
| DCP                        | 1.22       | 0.87–1.72 | 0.241 |              |     |     |
| Operation time             | 1.04       | 0.70–1.54 | 0.822 |              |     |     |
| Pringle time               | 0.88       | 0.60–1.29 | 0.513 |              |     |     |
| Bleeding                   | 0.91       | 0.64–1.28 | 0.606 |              |     |     |
| Transfusion                | 1.02       | 0.50–1.87 | 0.947 |              |     |     |
| Anatomic resection         | 0.90       | 0.63–1.27 | 0.570 |              |     |     |
| Multiple                   | 1.76       | 1.23–2.50 | 0.002 | 1.53         | 1.12–2.08 | 0.007 |
| Size                       | 1.55       | 1.10–2.20 | 0.012 | 1.62         | 1.18–2.22 | 0.002 |
| Differentiation grade      | 1.45       | 0.99–2.17 | 0.517 |              |     |     |
| Vascular invasion          | 1.38       | 0.96–1.96 | 0.077 | 1.34         | 0.94–1.86 | 0.094 |
| Tumor exposure             | 1.33       | 0.74–2.24 | 0.313 |              |     |     |
| Cirrhosis                  | 1.50       | 1.07–2.12 | 0.018 | 1.68         | 1.24–2.29 | < 0.001 |

HCV Hepatitis C virus infection, HBV Hepatitis B virus infection, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ICGR15 Indocyanine green clearance rate at 15 min, DCP Des-gamma carboxyprothrombin
patients with PBI compared with those without PBI. On the other hand, no association between PBI and survival was observed in non-B non-C HCC patients, which strongly suggests that PBI by itself is not a significant factor. However, when other significant immunosuppressive causes of liver damage co-exist such as HCV [31], human immunodeficiency virus infection [32], and immunosuppression therapy [18, 20], PBI or OBI may contribute to a worsening of the course of chronic liver disease. In this study, liver function tended to be worse in PBI patients with HCV-positive, which could account for the poorer overall survival of such patients despite of no significant difference of recurrence-free survival between the HCV-positive patients with and without PBI. Furthermore, surgical stress, as well as HCV infection, might also accelerate the deteriorative outcomes of PBI patients undergoing resection of HCC.

Compared with non-B non-C patients with PBI, overall survival rate at 5 years for HCV patients with PBI in this study was lower due to the high frequency of cirrhosis (advanced fibrosis), Child-Pugh classification B (poor liver function), and varices (portal hypertension). On the other hand, despite of the poorer liver function, survival rates of HCV patients without PBI were similar to those of non-B non-C patients without PBI, which also supports the idea that there may be some negative synergistic effects on the survival of patients after resection of HCC between PBI and HCV infections [31].

It is debatable whether PBI or OBI plays a pivotal role in the progression of fibrosis in HCV patients [5, 7, 10, 11]. In our study, the prevalence of patients with cirrhosis in the PBI group was not statistically different from those in the non-PBI group. Similarly, there was no association between PBI and the progression of cirrhosis in non-B non-C HCC patients, suggesting that PBI was not a predictor for cirrhosis, regardless of HCV-infection status. However, it should be noted that the population in this study was limited to candidates for surgery, and the results may not be simply comparable to that of previous studies.

Despite the numerous reports about the impact of PBI or OBI on HCV infection, there is only one report to date that analyzed survival after resection for patients with HCV-related HCC in association with PBI [15]. In contrast to our findings, they reported that the overall survival was not significantly different between the patients with and without PBI. This discrepancy may be attributed to the significantly higher frequency of anatomic resection in the HBcAb-positive group (69.7% vs 50.0%), despite similar liver function of the two groups. This might initiate the negative effects of PBI, and the positive effects of anatomic resection on survival.

On the other hand, the comparative study reported by Wu et al. focused on OBI in patients with non-B non-C HCC [16]. The period of recurrence-free survival was significantly longer, and the overall survival trended to be longer. Conversely, in another report by Itoh and colleagues, there was no significant differences in overall or recurrence-free survivals between non-B non-C HCC patients with and without PBI [15]. This is due to a higher recurrence-free survival rate at 5 years for patients without OBI (about 50%) in the former report [16], although overall and recurrence-free survival of patients with OBI are consistent with our data. In any case, there were a relatively small number of participants in their studies, and large-scale studies should be performed to justify these procedures in the future.
Conclusions

Our data that PBI negatively influenced the clinical outcomes in HCC patients with HCV infection that underwent HCC resection, but not in those without HCV. This might be attributed to the concept that PBI works as a co-effector with HCV to impact the outcomes for HCC patients.

Abbreviations

HBCAb: Anti-hepatitis B core antibody; HBsAb: Anti-hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; OBI: Occult hepatitis B virus infection; PBI: Prior hepatitis B virus infection

Acknowledgements

Not applicable

Authors’ contributions

YM designed the study, data acquisition, and wrote the initial draft of the manuscript; TT conceived of the study, and participated in its design and coordination and helped to draft the manuscript; HN, TH, and MMorig acquired the data; KM, TK, SM, MMorig revised the article for clinical content. All authors have read and approved the final version of the manuscript.

Funding

This research was supported by AMED under Grant Number JP18ha0102049h0001 and a grants-in-aid of The 106th Annual Congress of JSS Memorial Surgical Research Fund, Tokyo, Japan. The funding body supported the data collection used in this study. The funding body has no role in the design of the study and analysis and interpretation of data and in writing the manuscript.

Availability of data and materials

Data and materials analyzed in this study are not available due to the protection of individual privacy, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Each participant provided written, informed consent, and this study was approved by the institutional review board of Nihon University (RK-141209-4).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Digestive Surgery, Nihon University School of Medicine, 30-1, Oyaguchikami-cho, Itabashi-ku, Tokyo 173-8610, Japan. 2Department of Infectious Diseases, University of Tokyo Faculty of Medicine, Tokyo, Japan. 3Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan.

Received: 1 March 2019 Accepted: 15 August 2019

Published online: 19 August 2019

References

1. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.
2. Matsuzaki Y, Sato M, Saito Y, Karube M, Doy M, Shoda J, et al. The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study. J Exp Clin Cancer Res. 1999;18:379–89.
3. Tamaro A, Nishiguchi S, Kubo S, Narimatsu T, Habu D, Takeda T, et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol. 2003;71:492–8.
4. Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008;43:849–56.
5. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, et al. Previous hepatitis B virus B infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int. 2003;23:12–8.
6. Kubo S, Tamori A, Ohba K, Shuto T, Yamamoto T, Tanaka H, et al. Previous or occult hepatitis B virus B infection in hepatitis C virus-associated hepatocellular carcinoma without hepatitis fibrosis. Dig Dis Sci. 2001;46:408–14.
7. Sagrenelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, et al. Wrolologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology, 2000;32:1106–10.
8. Ikeda K, Manusawah H, Osaki Y, Nakamura T, Kitaizum N, Yamahata Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007;146:649–56.
9. Squatrito G, Cacciola I, Allbrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the clinical outcome of chronic hepatitis C patients treated with pegylated interferon and ribavirin. J Med Virol. 2010;82:747–54.
10. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007;46:350–6.
11. Levast M, Lamat S, Thelu MA, Nicod S, Plages A, Cheveau A, et al. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. J Med Virol. 2005;75:247–53.
12. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:344–42.
13. Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25:247–53.
14. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, et al. Occult hepatitis B virus infection and prior hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res. 2015;193:153–60.
15. Coppola N, Onorato L, Pisaturro M, Macera M, Sagrenelli C, Martinelli S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C patients. World J Gastroenterol. 2015;21:11931–40.
16. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9.
17. Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014;15:21455–67.
18. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.
19. Raimondo G, Pollicino T, Cacciola I, Squatrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–70.
20. El-Sherif A, Abou-Shady M, Abou-Zeid H, Elwassief A, Elbahrawy A, Ueda Y, et al. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol. 2009;44:359–64.
21. Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23–9.
22. Kokudo N, Hasegawa K, Akahane M, Igaki H, Iizumi N, Ikida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the
25. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304.

26. Yamazaki S, Takayama T, Nakamura M, Higaki T, Matsuoka S, Mizuno S, et al. Prophylactic impact of endoscopic treatment for esophageal varices in liver resection: a prospective study. J Gastroenterol. 2014;49:917–22.

27. Takayama T, Makuuchi M, Kubota K, Harihara Y, Hui AM, Sano K, et al. Randomized comparison of ultrasonic vs clamp transection of the liver. Arch Surg. 2001;136:922–8.

28. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

29. Midorikawa Y, Kubota K, Takayama T, Toyoda H, Ijichi M, Torzilli G, et al. A comparative study of postoperative complications after hepatectomy in patients with and without chronic liver disease. Surgery. 1999;126:484–91.

30. Midorikawa Y, Takayama T, Shimada K, Nakayama H, Higaki T, Moribuchi M, et al. Marginal survival benefit in the treatment of early hepatocellular carcinoma. J Hepatol. 2013;58:305–11.

31. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet. 2005;365:638–40.

32. Vento S, di Perri G, Luzzati R, Garofano T, Concia E, Bassetti D. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet. 1989;1:332–3.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.